Anatumomab mafenatox

Drug Profile

Anatumomab mafenatox

Alternative Names: ABR 214936; PNU 214936; TTS CD2

Latest Information Update: 04 Oct 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Active Biotech
  • Class Antineoplastics; Immunoglobulin fusion proteins; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-small cell lung cancer; Pancreatic cancer; Renal cancer

Most Recent Events

  • 10 May 2004 Discontinued - Phase-I for Non-small cell lung cancer in Europe (unspecified route)
  • 10 May 2004 Discontinued - Phase-II for Non-small cell lung cancer in USA (unspecified route)
  • 10 May 2004 Discontinued - Phase-II for Pancreatic cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top